Just a moment, the page is loading...

GSK-49653/351




A 12 month randomized, double-blind, placebo-controlled, magnetic resonance imaging study to evaulate the effect of rosiglitazone on the structure and composition of carotid atherosclerotic plaques in subjects with type 2 diabetes
rosiglitazone
49653/351
Diabetes Mellitus, Type 2
Phase 4
An analysis-ready dataset is not available for this study. A link to ClinicalTrials.gov and an NCTID number are not available for this study because the study is not in scope of regulatory requirements to register studies.
September 2013